LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

Search

MacroGenics Inc

Avatud

SektorTervishoid

1.53 -0.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.48

Max

1.59

Põhinäitajad

By Trading Economics

Sissetulek

4.8M

-36M

Müük

9M

22M

Kasumimarginaal

-162.992

Töötajad

341

EBITDA

5.7M

-33M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+183.02% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

34M

127M

Eelmine avamishind

2.18

Eelmine sulgemishind

1.53

Uudiste sentiment

By Acuity

50%

50%

183 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. sept 2025, 22:39 UTC

Omandamised, ülevõtmised, äriostud

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. sept 2025, 16:43 UTC

Suurimad hinnamuutused turgudel

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. sept 2025, 16:42 UTC

Suurimad hinnamuutused turgudel

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. sept 2025, 16:35 UTC

Suurimad hinnamuutused turgudel

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. sept 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. sept 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. sept 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Expects Commercial Launch in 2029

15. sept 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. sept 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. sept 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. sept 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. sept 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. sept 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. sept 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. sept 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. sept 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. sept 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. sept 2025, 17:50 UTC

Omandamised, ülevõtmised, äriostud

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. sept 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. sept 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. sept 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. sept 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. sept 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

183.02% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  183.02%

Kõrge 5 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

183 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat